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Abstract  
Introduction: Haematological malignancies (HM) are malignant disorders involving the haemopoietic system. 
Oxidative stress has been implicated in the development and evolution of these disorders. To measure total 
antioxidant capacity (TAC) in patients with HM and to determine if any, the relationship between TAC and total 
lipid in these patients. 
Presentation of the case: This is a multicentre cross sectional study. Patients were sampled with self 
administered questionnaire that documented their biodata and the various types of haematological malignancies 
they had.  Blood samples from 31 patients with HM and 11 controls were assessed for TAC and total lipids 
using RelAssay and TECO diagnostic kits respectively. Difference between means was compared using student 
T-test. The relationship between TAC and TL was measured using Pearson’s correlation coefficient.  
Total antioxidant capacity was significantly lower in patients with HM. The mean total lipid concentrations of 
the cancer patients were higher than in the controls but this was not statistically significant (p>0.05). A 
negative correlation was found between TAC and total lipids in patients with HM.  
Conclusion: This study has further affirmed that patients with HM have a significantly lower antioxidant 
activity. However, further investigations are required to fully elucidate the mechanism and clinical implications 
of reduced TAC in these patients.  
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Introduction 
Haematological malignancies (HM) are cancers 
of the blood, bone marrow and lymphatic tissues. 
They include leukaemias (lymphoid and 
myeloid), lymphomas (non Hodgkins and 
Hodgkin’s) and plasma cell neoplasm.  
Oxidative stress is an imbalance in the redox 
potential of the body in favour of oxidizing 
reactions over antioxidant activities as a result 
of increased production of reactive oxidizing 
species (ROS) and depletion of neutralizing 
antioxidant. When the body is unable to control 
this stress, disorders develop.
1
 Oxidative stress 
has been implicated in the development and 
evolution of HM.
2,3
 The ROS may act as 
initiators and or promoters of carcinogenesis 
through their mutagenic effect on the DNA.
4-6
 
Furthermore, cancer chemotherapeutic agents 
used in the management of HM also generate 
ROS some of which may in addition to 
destroying the cancer cells have lethal effects of 
normal host cells.
1 
The body antioxidant 
mechanisms are responsible for the 
neutralization of ROS. It comprise of both 
enzymatic and non enzymatic components. The 
non enzymatic components include exogenous 
vitamins such as vitamins A, C, E; reduced 
glutathione (GSH) and other endogenous 
proteins. Enzymatic component include 
superoxide dismutase (SOD), catalase (CAT) and 
glutathione peroxidase (GPX).  
Several studies on oxidative stress in patients 
with haematological malignancies have focused 
on specific components of the antioxidant 
system and their findings have not been 
consistent.
7-10
 A study on the total antioxidant 
capacity (TAC) which is a measure of the sum of 
endogenous and food derived antioxidant 
capacity measurable with various methods
11,12
 
may be a better measure of oxidative stress in 
haematological malignancies. There is paucity of 
studies on total antioxidant capacity in patients 
with HM especially in Nigeria. We hypothesized 
that patients with HM have reduced TAC. The 
objective of this study therefore is to measure 
the TAC in patients with HM and to determine if 
there is any the relationship between TAC and 
plasma total lipids (TL). 
Patients and Methods 
Study Design: This is a multicentre cross 
sectional studies conducted in two areas with a 
tertiary health facility namely University of 
Benin Teaching Hospital (UBTH), Benin City 
with a 700 bed-space capacity and Delta state 
University Teaching Hospital (DELSUTH), 
Oghara in Nigeria. The total catchment’s 
population of the hospital used is 15.3 million 
and are major referral centre serving the South 
South geopolitical zone of Nigeria. Controls 
recruited from the study areas comprise 
non-cancer healthy volunteers who were 
seronegative for HIV 1 and 2, hepatitis B surface 
antigen and hepatitis C virus. Patients were 
sampled with self administered questionnaire 
that documented their age, gender and 
the`````````` various types of haematological 
malignancies they had.  The cytomorphological 
diagnostic techniques recommended by the 
various Cancer Institutes’ including blood 
smears, bone marrow studies, lymph node 
histology and immunohistochemistry were 
applied in the diagnosis of HM patients in this 
study. The patients were placed on the 
appropriate anti-neoplastic agents for the various 
HM. All the participants gave informed consent 
after the study was approved by the hospital 
ethical committee.       
Laboratory Assay Methods 
Sample Collection: Ten milliliters of venous 
blood was aseptically obtained from each 
participant after 12-14 hours of fasting. In this 
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way, the possible influence of dietary factors on 
the level of free radicals was avoided. The 
samples were dispensed into specimen bottles 
without anticoagulants and were allowed to clot 
and retract. The blood was thereafter centrifuged 
for 10-15 minutes at 3000rpm and the clear sera 
harvested with clean Pasteur pipettes, put in sera 
bottles and stored at -20
0
C until analyzed. 
TAC Assay Method:  TAC was measured with 
TAC assay kit manufactured by RelAssay 
Diagnostics (Turkey) Lot number RL020. The 
antioxidants in the sample reduce dark blue 
green coloured radicals to colourless forms. The 
change in absorbance at 660nm is related to the 
TAC of the sample in Trolox Equivalent/L.
 
Total Lipids Assay: Total lipids were assayed 
using a laboratory total lipid kit manufactured by 
TECO Diagnostics (Anaheim, USA). The 
sulfo-phospho-vanillin (SPV) colorimetric 
method for the determination of total lipids 
described by Charbol et al
13 
and modified by 
various investigators
14,15 
was used. The assay 
was quality controlled using controls supplied 
alongside. 
Statistical Analysis: The means and standard 
errors of mean (SEM) of TAC and total lipids for 
both patients and controls were computed using 
the statistical Package for Social Sciences 
(SPSS) version 16. T- test was used to calculate 
the difference in means of both groups. The one 
way analysis of variance (ANOVA) test was used 
to compare the difference in means between the 
various HM with more than one participant. The 
relationship between TAC and TL was 
determined using Pearson’s correlation test. 
P-values < 0.05 was considered significant.  
Results 
A total of 31 patients with hematological cancers 
were seen during the study period (July to 
August, 2012). This comprised of 11 males 
(35.5%) and 20 females (64.5%) with a 
male-to-female ratio of 0.6:1. These were 
compared with 10 non-cancer apparently healthy 
subjects (8 males and 2 females) who were 
prescreened and found without any history of 
clinical disorder. The mean age of the patients 
group was 57.1±12.8 years with a median age of 
59 years (range, 30-80years)  while the mean 
age for the control was 31.8±4.3 years with a 
median age of 32.5years (range, 26-39 years)    
The study population of 31 patients with 
haematological malignancies comprised of 3 
(9.7%) acute leukaemias (2 acute lymphoblastic 
and 1 acute myeloblastic leukaemias), 9 (29.0%) 
chronic lymphocytic leukaemias, 8 (25.8%) 
lymphomas (7 non Hodgkin’s lymphoma and 1 
Hodgkin lymphoma), 7 (22.6%) multiple 
myeloma and 4 (12.9%) myeloproliferative 
diseases (2 chronic myeloid leukaemias, 1 
Polycythaemia Rubra Vera and 1 essential 
thrombocythaemia). Chronic leukaemias and 
Lymphomas were the common haematological 
cancers seen during the study period.  
The mean and standard error of mean of total 
antioxidant capacity for the merged cancer 
patients and the controls were 3.8  0.3 and 
5.2 0.3 Trolox Equivalent/L respectively as 
revealed in table 1. This shows that the mean 
TAC of the patients were significantly lower 
than the mean level observed in controls 
(p<0.05). The mean total lipid concentrations of 
the cancer patients were higher than in the 
controls but this was not statistically significant 
(p>0.05). The analysis of variation (ANOVA) 
test did not show any significant difference in 
the means between the various haematological 
malignancies. Table 2, shows the descriptive 
statistics of patients with various haematological 
malignancies. A negative correlation however 
exist between TAC and total lipids in the 
patients group (r=0.48 and p<0.01) as shown in 
table 3.   
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Table 1 the mean standard error of mean of total antioxidant capacity and total lipids in both patients and 
control 
 
Parameters    Patients   Control     P Value 
TAC 3.8 ± 0.3 5.2 ± 0.3 0.005 
TLC 584.6±29.0 564.4±52.0 ns 
TAC-total antioxidant capacity; TLC-total lipids concentration; ns-not significant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Correlation between TAC and total lipids in patients with hematological malignancies 
 
Table 2 Descriptive Statistics of the various hematological malignancies 
HAEMATOLOGICAL MALIGNANCIES 
N 
TAC 
Mean ± SEM 
TL 
Mean ±SEM 
 ACUTE LEUKAEMIA 3 3.8 ± 1.1   616.9 ± 40.1 
CLL 9 3.7 ± 0.6   622.5 ± 70.3 
NHL 7 3.7 ± 0.5   600.6 ± 75.8 
MYELOMA 7 3.8 ± 0.5   545.3 ± 27.8 
MPD 4 3.7 ± 0.8   570.4 ± 74.3 
HD 1 4.7 ± 0.0   365.1 ± 0.0 
TOTAL 31 3.8 ± 0.3   584.6 ± 29.0 
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Table 3 the correlation between TAC and total lipids in patients group 
 
  TAC TOTAL LIPIDS 
TAC Pearson Correlation (r) 1 -.496
**
 
Sig. (2-tailed)  .005 
N 31 31 
TOTAL LIPIDS Pearson Correlation (r) -.496
**
 1 
Sig. (2-tailed) .005  
N 31 31 
 
Discussion 
There are limited studies on total antioxidant capacity 
(TAC) in patients with haematological malignancies 
(HM) in our environment. Several studies have evaluated 
enzymatic antioxidant activities in patients with HM and 
their findings are not consistent. Devi et al 
7
reported 
increased superoxide dismutase (SOD) and GPX in 
patients with HM but Sonali et al
8
 reported the reverse.  
Oltra et al
3
 reported a lower SOD and catalase (CAT) 
in patients with CLL. Similarly reduced SOD and CAT 
have been documented in patients with ALL.
9
 These 
inconsistent findings may suggest that TAC may be a 
better assay in measuring antioxidant status. Variation in 
enzymatic activities may be attributable to the redox 
buffering potential of non enzymatic antioxidant 
component such as GSH, responsible for the maintenance 
of the overall redox balance in cells.
16 
Papageorgiou et al
17
 in a study on TAC in children 
with HM reported no significant difference in the TAC in 
patients and control groups prior to commencement of 
chemotherapy. However, on commencement of 
chemotherapy, there was a progressive decline in TAC in 
patient group. The decrease in TAC was attributed to the 
oxidant stress of chemotherapy. Kuku et al
18
 reported a 
significant decline in enzyme antioxidant capacity of 
patients with multiple myeloma undergoing 
chemotherapy. 
In this study, we observed a significantly lower TAC in 
our patients’ compared to controls. Though there is a 
disparity in age between our patient and control groups, it 
has been shown that TAC does not differ significantly 
with age.
19, 20
 Chrzczanowicz et al
19
 in a study of 422 
males’ with an age range of 19.2 – 89 years demonstrate 
that TAC does not differ significantly with age. The 
significant difference in the TAC of both study groups 
may be attributable to the oxidative stress of 
chemotherapy and low intake of exogenous antioxidants. 
The tumoricidal action of anti-cancer drugs has been 
suggested to be mediated through a free-radical 
dependent mechanism. Kelkel et al
21
 in a review on 
antioxidants documented that some dietary antioxidants 
have the potential of preventing and treating 
haematological malignancies. However, more 
randomized studies may be required to validate this 
report. 
   
Haematological malignancies as well as other cancers 
have been associated with abnormal lipid 
metabolism.
22-24 
Several of these indicate that patients’ 
with malignancies tend to have hypocholesterolaemia 
and hypertriglyceridaemia. There are dearth of studies on 
the correlation between TAC and lipids. Though in our 
study there is no significant difference in the total lipids 
between the patient and control groups, we found a 
negative correlation between TAC and total lipids. 
However there may be need for further studies to 
establish the relationship between the various lipid 
fractions and TAC. 
In conclusion, patients with HM have significantly low 
TAC than controls and there is a negative correlation 
between TAC and total lipids in these patients.  Further 
investigation is required in order to fully determine the 
correlation between TAC and the various lipid fractions. 
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